Related Experiment Video

Updated: Jul 5, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Inhibition of osteopontin dependent carcinogenesis

Shailendra Kapoor1

  • 1shailendrakapoor@yahoo.com

Journal of Cancer Research and Clinical Oncology
|May 21, 2008
PubMed

Insights

Osteopontin drives cancer growth and spread. Inhibiting this molecule, using agents like argatroban, shows promise in controlling various systemic malignancies.

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Osteopontin (OPN) is a key molecule implicated in promoting cellular proliferation and metastasis in systemic malignancies.
  • Understanding OPN's role is crucial for developing targeted cancer therapies.

Discussion:

  • Inhibiting OPN-mediated tumorigenesis offers a promising strategy for cancer control.
  • Several agents, including argatroban, agelastatin A, and selenium, are being investigated as OPN inhibitors.
  • Argatroban has demonstrated efficacy in reducing breast cancer cell growth and lymphatic metastasis.

Key Insights:

  • Anti-OPN antibodies and antisense OPN RNA have shown success in inhibiting tumor growth in prostate carcinomas and osteosarcomas.
  • Targeting OPN pathways presents a viable therapeutic avenue for diverse cancers.

Outlook:

  • Further research is needed to identify and develop more potent OPN inhibitors.
  • Expanding the clinical application of existing OPN-targeting agents is essential for managing cancer progression.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...